Cancer genomic profiling is a laboratory technique used in the generation of personalized medicine. The genomic profiling evaluates all the genes present in tumor to determine an optimal course of treatment for an individual.
DATE: November 12, 2019TIME: 10:00am PSTDirect measurement of copy number by droplet-based shallow sequencing of genomic DNA has the potential to provide new insights into tumor heterog...
DATE: October 30, 2019TIME: 7:00am PDTJoin us for a webinar to learn how to apply single cell methods to study cancer. Dr. William Greenleaf, Associate Professor from Stanford Universit...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Acute lymphoblastic leukemia is the most common cancer in children and adolescents. While current treatments have resulted in 85-90% cure, the remaining 10-15% cases represent the leading cau...
Early detection is critical for improved survival in melanoma. Melanocytic nevi are extremely common benign tumors that mimic melanoma and are therefore commonly biopsied. Currently, the dete...
DATE: September 17, 2019TIME: 9:00am PTSpatial Transcriptomics (ST) technology reveals gene expression from up to one thousand spots across a tissue section. In this webinar, Dr. H...
The emergence and spread of antimicrobial-resistant (AMR) bacteria and resistance mechanisms pose a serious challenge to laboratories in both hospital clinical microbiology and public health...
DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
DNA profiling tools to teach undergraduate students about forensics generally utilize the PV92 Alu and D1S80 VNTR markers, but are both limited in scope. In contrast, advanced profiling syste...
Tumor heterogeneity is a hallmark of cancer and can have significant impact on identifying drivers, including those that may be therapeutically relevant. Although, the traditional sequencing...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Virtually all tumors are genetically heterogeneous, containing subclonal populations of cells that are defined by distinct mutations. Subclones can have unique phenotypes that influence disea...
DATE: June 19, 2019TIME: 8:00am PDT, 11:00am EDT Approximately 80% of all cancers are known to be affected by both somatic mutations and copy number changes. Furthermore, r...
Genetic drivers of cancer can be dysregulated through epigenetic modifications of DNA. Although the critical role of DNA 5-methylcytosine (5mC) in the regulation of transcription is recognize...
The BRCA1 and BRCA2 genes represent the best examples of the modern understanding of cancer molecular genetics. Testing for germline and somatic mutations in BRCA 1/2 has gradually become com...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
DATE: February 26, 2019TIME: 9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
DATE: November 28, 2018TIME: 7:00AM PSTSingle-cell genomics enables a deep dive into the mechanisms responsible for health and disease, in areas from cancer biology to neurob...
The use of human pluripotent stem cells (hPSCs) for in vitro disease-modeling is limited by the lack of robust and efficient protocols for the differentiation of relevant adult cell types. Pr...
With significant decrease in the cost of sequencing in numerous commercial as well as cancer center–driven initiatives, genomic profiling is increasingly becoming routine across multipl...
DATE: October 23, 2018TIME: 9:00AM PDTIxodes scapularis is the principal vector of the Lyme disease spirochete, Borrelia burgdorferi. I. scapularis genome was the first and only...
Recent work has identified epigenomic features of distal regulatory elements to be dynamic and defining indicators of cellular specification and transformation. Of particular relevance is our...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
DATE: November 12, 2019TIME: 10:00am PSTDirect measurement of copy number by droplet-based shallow sequencing of genomic DNA has the potential to provide new insights into tumor heterog...
DATE: October 30, 2019TIME: 7:00am PDTJoin us for a webinar to learn how to apply single cell methods to study cancer. Dr. William Greenleaf, Associate Professor from Stanford Universit...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Acute lymphoblastic leukemia is the most common cancer in children and adolescents. While current treatments have resulted in 85-90% cure, the remaining 10-15% cases represent the leading cau...
Early detection is critical for improved survival in melanoma. Melanocytic nevi are extremely common benign tumors that mimic melanoma and are therefore commonly biopsied. Currently, the dete...
DATE: September 17, 2019TIME: 9:00am PTSpatial Transcriptomics (ST) technology reveals gene expression from up to one thousand spots across a tissue section. In this webinar, Dr. H...
The emergence and spread of antimicrobial-resistant (AMR) bacteria and resistance mechanisms pose a serious challenge to laboratories in both hospital clinical microbiology and public health...
DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
DNA profiling tools to teach undergraduate students about forensics generally utilize the PV92 Alu and D1S80 VNTR markers, but are both limited in scope. In contrast, advanced profiling syste...
Tumor heterogeneity is a hallmark of cancer and can have significant impact on identifying drivers, including those that may be therapeutically relevant. Although, the traditional sequencing...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Virtually all tumors are genetically heterogeneous, containing subclonal populations of cells that are defined by distinct mutations. Subclones can have unique phenotypes that influence disea...
DATE: June 19, 2019TIME: 8:00am PDT, 11:00am EDT Approximately 80% of all cancers are known to be affected by both somatic mutations and copy number changes. Furthermore, r...
Genetic drivers of cancer can be dysregulated through epigenetic modifications of DNA. Although the critical role of DNA 5-methylcytosine (5mC) in the regulation of transcription is recognize...
The BRCA1 and BRCA2 genes represent the best examples of the modern understanding of cancer molecular genetics. Testing for germline and somatic mutations in BRCA 1/2 has gradually become com...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
DATE: February 26, 2019TIME: 9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
DATE: November 28, 2018TIME: 7:00AM PSTSingle-cell genomics enables a deep dive into the mechanisms responsible for health and disease, in areas from cancer biology to neurob...
The use of human pluripotent stem cells (hPSCs) for in vitro disease-modeling is limited by the lack of robust and efficient protocols for the differentiation of relevant adult cell types. Pr...
With significant decrease in the cost of sequencing in numerous commercial as well as cancer center–driven initiatives, genomic profiling is increasingly becoming routine across multipl...
DATE: October 23, 2018TIME: 9:00AM PDTIxodes scapularis is the principal vector of the Lyme disease spirochete, Borrelia burgdorferi. I. scapularis genome was the first and only...
Recent work has identified epigenomic features of distal regulatory elements to be dynamic and defining indicators of cellular specification and transformation. Of particular relevance is our...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
